Finanzen von Autonomix Medical Inc (AMIX)AMIXAutonomix Medical Inc

Evaluating the bottom line, Autonomix Medical Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -315.99%, provide a clear picture of how effectively AMIX converts its operational activities into shareholder value.

In the context of the broader market, AMIX competes directly with industry leaders such as BRTX and ITOC. With a market capitalization of $5.47M, it holds a significant position in the sector. When comparing efficiency, AMIX's gross margin of N/A stands against BRTX's 68.13% and ITOC's 79.03%. Such benchmarking helps identify whether Autonomix Medical Inc is trading at a premium or discount relative to its financial performance.

The company has consistently reported net losses, with Q2 2026 showing a loss of $7,451,000. The EPS has been negative, with the latest at -5.02, indicating ongoing financial challenges.